{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T21:11:40Z","timestamp":1783545100785,"version":"3.55.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T00:00:00Z","timestamp":1634947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T00:00:00Z","timestamp":1634947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s40264-021-01119-2","type":"journal-article","created":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T10:02:42Z","timestamp":1634983362000},"page":"1355-1364","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Long-Term Safety and Tolerability of Fremanezumab for Migraine Preventive Treatment in Japanese Outpatients: A Multicenter, Randomized, Open-Label Study"],"prefix":"10.1007","volume":"44","clinical-trial-number":[{"clinical-trial-number":"nct03303105","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9385-7991","authenticated-orcid":false,"given":"Fumihiko","family":"Sakai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0399-6590","authenticated-orcid":false,"given":"Norihiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiharu","family":"Usuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiro","family":"Iba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Isogai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8034-7984","authenticated-orcid":false,"given":"Nobuyuki","family":"Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,23]]},"reference":[{"issue":"4","key":"1119_CR1","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/head.12055","volume":"53","author":"AM Blumenfeld","year":"2013","unstructured":"Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC, Varon SF, Maglinte GA, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache. 2013;53(4):644\u201355.","journal-title":"Headache"},{"issue":"8","key":"1119_CR2","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1111\/j.1526-4610.2011.01986.x","volume":"51","author":"EW Loder","year":"2011","unstructured":"Loder EW, Rizzoli P. Tolerance and loss of beneficial effect during migraine prophylaxis: clinical considerations. Headache. 2011;51(8):1336\u201345.","journal-title":"Headache"},{"issue":"1","key":"1119_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s10194-019-1012-1","volume":"20","author":"K Ueda","year":"2019","unstructured":"Ueda K, Ye W, Lombard L, Kuga A, Kim Y, Cotton S, et al. Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme. J Headache Pain. 2019;20(1):68.","journal-title":"J Headache Pain"},{"issue":"9","key":"1119_CR4","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1177\/0333102419835465","volume":"39","author":"M Bonafede","year":"2019","unstructured":"Bonafede M, Wilson K, Xue F. Long-term treatment patterns of prophylactic and acute migraine medications and incidence of opioid-related adverse events in patients with migraine. Cephalalgia. 2019;39(9):1086\u201398.","journal-title":"Cephalalgia"},{"issue":"6","key":"1119_CR5","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0333102414547138","volume":"35","author":"Z Hepp","year":"2015","unstructured":"Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35(6):478\u201388.","journal-title":"Cephalalgia"},{"issue":"9","key":"1119_CR6","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1111\/head.13157","volume":"57","author":"JM Woolley","year":"2017","unstructured":"Woolley JM, Bonafede MM, Maiese BA, Lenz RA. Migraine prophylaxis and acute treatment patterns among commercially insured patients in the United States. Headache. 2017;57(9):1399\u2013408.","journal-title":"Headache"},{"issue":"1","key":"1119_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.18553\/jmcp.2014.20.1.22","volume":"20","author":"Z Hepp","year":"2014","unstructured":"Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 2014;20(1):22\u201333.","journal-title":"J Manag Care Pharm"},{"issue":"5","key":"1119_CR8","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1177\/0333102416678382","volume":"37","author":"Z Hepp","year":"2017","unstructured":"Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P, et al. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia. 2017;37(5):470\u201385.","journal-title":"Cephalalgia"},{"key":"1119_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/164_2018_201","volume-title":"Calcitonin gene-related peptide (CGRP) mechanisms. Handbook of experimental pharmacology","author":"L Edvinsson","year":"2019","unstructured":"Edvinsson L. Role of CGRP in migraine. In: Brain SD, Geppetti P, editors. Calcitonin gene-related peptide (CGRP) mechanisms. Handbook of experimental pharmacology. Cham: Springer International Publishing; 2019. p. 121\u201330."},{"issue":"6","key":"1119_CR10","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","volume":"14","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies\u2014successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338\u201350.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"1119_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/head.13456","volume":"59","author":"American Headache Society","year":"2019","unstructured":"American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59(1):1\u201318.","journal-title":"Headache"},{"issue":"3","key":"1119_CR12","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1177\/0333102418821662","volume":"39","author":"DW Dodick","year":"2019","unstructured":"Dodick DW. CGRP ligand and receptor monoclonal antibodies for migraine prevention: evidence review and clinical implications. Cephalalgia. 2019;39(3):445\u201358.","journal-title":"Cephalalgia"},{"issue":"19","key":"1119_CR13","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018;319(19):1999\u20132008.","journal-title":"JAMA"},{"issue":"22","key":"1119_CR14","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113\u201322.","journal-title":"N Engl J Med"},{"key":"1119_CR15","doi-asserted-by":"publisher","first-page":"e2487","DOI":"10.1212\/WNL.0000000000010600","volume":"95","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Silberstein SD, Yeung PP, Cohen JM, Ning X, Yang R, et al. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study. Neurology. 2020;95:e2487\u201399.","journal-title":"Neurology"},{"key":"1119_CR16","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/head.14169","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Suzuki N, Kim B-K, Igarashi H, Hirata K, Takeshima T, et al. Efficacy and safety of fremanezumab for chronic migraine prevention: multicenter, randomized, double-blind, placebo controlled, parallel-group trial in Japanese and Korean patients. Headache. 2021;61:1092\u2013101.","journal-title":"Headache"},{"key":"1119_CR17","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/head.14178","volume":"61","author":"F Sakai","year":"2021","unstructured":"Sakai F, Suzuki N, Kim BK, Tatsuoka Y, Imai N, Ning X, et al. Efficacy and safety of fremanezumab for episodic migraine prevention: multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache. 2021;61:1102\u201311.","journal-title":"Headache"},{"issue":"16","key":"1119_CR18","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.jpsychires.2010.04.025","volume":"44","author":"JC Mundt","year":"2010","unstructured":"Mundt JC, Greist JH, Gelenberg AJ, Katzelnick DJ, Jefferson JW, Modell JG. Feasibility and validation of a computer-automated Columbia-Suicide Severity Rating Scale using interactive voice response technology. J Psychiatr Res. 2010;44(16):1224\u20138.","journal-title":"J Psychiatr Res"},{"issue":"8","key":"1119_CR19","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1023\/A:1026119331193","volume":"12","author":"M Kosinski","year":"2003","unstructured":"Kosinski M, Bayliss MS, Bjorner JB, Ware JE Jr, Garber WH, Batenhorst A, et al. A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res. 2003;12(8):963\u201374.","journal-title":"Qual Life Res"},{"issue":"6 Suppl. 1","key":"1119_CR20","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1212\/WNL.56.suppl_1.S20","volume":"56","author":"WF Stewart","year":"2001","unstructured":"Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001;56(6 Suppl. 1):S20\u20138.","journal-title":"Neurology"},{"key":"1119_CR21","unstructured":"Committee for Proprietary Medicinal Products. ICH topic E 1: population exposure: the extent of population exposure to assess clinical safety. CPMP\/ICH\/375\/95. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500002747.pdf. Accessed 18 Dec 2020."},{"key":"1119_CR22","unstructured":"Ning X, Cohen JM, Wu M, Nagaoka T, Sakai F. Efficacy and safety of fremanezumab versus placebo for the preventive treatment of episodic migraine (EM) and chronic migraine (CM) in a subpopulation of Japanese patients: results from the randomized, double-blind, phase 3 HALO studies. Presented at the 48th Annual Meeting of the Japanese Headache Society; 7\u20138 November 2020."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01119-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-021-01119-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01119-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T16:29:05Z","timestamp":1699720145000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-021-01119-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,23]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1119"],"URL":"https:\/\/doi.org\/10.1007\/s40264-021-01119-2","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,23]]},"assertion":[{"value":"31 August 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Otsuka Pharmaceutical Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"FS reports being an advisor for Otsuka Pharmaceutical Co. Ltd., Eli Lilly, and Amgen. NS reports personal fees from Otsuka Pharmaceutical Co., Ltd. XN is a full-time employee of Teva Branded Pharmaceutical Products R&D. MI, CU, KI, YI, and NK are full-time employees of Otsuka Pharmaceutical Co., Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The institutional review board or independent ethics committee\/ethics committee approved this protocol.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Patient consent was documented on a written informed consent form, which was accompanied by written information for patients and the informed consent forms were approved by the same institutional review board or independent ethics committee\/ethics committee that approves this protocol. Each written information for patients and informed consent form complied with the International Conference on Harmonisation Good Clinical Practice Guideline 18 and local regulatory requirements.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Anonymized individual participant data that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"FS, NS, XN, MI, CU, and KI were involved in the conception or design of the study. FS, NS, MI, CU, and KI were involved in the data acquisition or analysis. All authors were involved in the interpretation of the data as well as drafting and revising the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}